

Supporting information

Table S1. The best response of two groups before progression.

	TKI+RT	TKI	<i>P</i> value
Intracranial			
CR	4	1	
PR	61	35	
SD	10	10	
PD	2	11	
ORR	65 (84.4%)	36 (63.2%)	0.005
DCR	75 (97.4%)	46 (80.7%)	0.001
Systematic			
CR	0	0	
PR	62	33	
SD	9	10	
PD	6	14	
ORR	62 (80.5%)	33 (57.9%)	0.004
DCR	71 (92.2%)	43 (74.5%)	0.007

Table S2. Univariate analysis and multivariate analysis of PFS.

Variable	Univariate			Multivariate		
	HR	95% CI	<i>P</i>	HR	95% CI	<i>P</i>
Age						
≤ 60	1					
> 60	0.823	0.562-1.204	0.315			
Gender						
male	1					
female	0.827	0.574-1.192	0.309			
Smoking						
Never	1					
Current / ex-smoking	1.249	0.855-1.827	0.250			
KPS						
≤ 80	1					
> 80	0.987	0.692-1.406	0.941			
Number of brain metastases						
≤ 3	1					
> 3	0.892	0.625-1.273	0.528			
Symptoms						
No	1					
Yes	0.618	0.423-0.904	0.013			
Extracranial metastases						
No	1					
Yes	1.127	0.780-1.628	0.524			
EGFR mutation						
Del-19	1					
21-L858R	1.080	0.753-1.549	0.674			
Other	1.411	0.511-3.901	0.507			
Brain radiotherapy						
No	1			1		
Yes	0.613	0.428-0.879	0.008	0.675	0.468-0.973	0.035
EGFR TKI						
Erlotinib	1			1		
Icotinib	2.314	1.277-4.192	0.006	2.347	1.285-4.285	0.005

Gefitinib	2.209	1.162-4.198	0.016	2.237	1.169-4.282	0.015
Other	1.156	0.261-5.116	0.849	1.600	0.357-7.174	0.539
Combination of CT or AAD						
No	1			1		
Yes	0.567	0.394-0.815	0.002	0.570	0.395-0.823	0.003

Table S3. Univariate analysis and multivariate analysis of OS.

Variable	Univariate			Multivariate		
	HR	95% CI	P	HR	95% CI	P
Age						
≤ 60	1			1		
> 60	1.728	1.052-2.838	0.031	1.411	0.839-2.374	0.194
Gender						
male	1					
female	1.357	0.806-2.284	0.251			
Smoking						
Never	1					
Current / ex-smoking	0.969	0.571-1/645	0.907			
KPS						
≤ 80	1			1		
> 80	0.607	0.370-0.995	0.048	0.657	0.377-1.148	0.140
Number of brain metastases						
≤ 3	1					
> 3	1.075	0.655-1.763	0.775			
Symptoms						
No	1					
Yes	0.523	0.303-0.904	0.020			
Extracranial metastases						
No	1					
Yes	1.556	0.901-2.685	0.113			
EGFR mutation						
Del-19	1			1		
21-L858R	2.116	1.248-3.589	0.005	2.460	1.415-4.277	0.001
Other	1.713	0.486-6.036	0.402	2.671	0.667-10.695	0.165
Brain radiotherapy						
No	1			1		
Yes	0.558	0.342-0.913	0.020	0.550	0.327-0.927	0.025
EGFR TKI						
Erlotinib	1			1		
Icotinib	2.523	1.103-5.771	0.028	2.930	1.184-7.256	0.020
Gefitinib	2.178	0.921-5.150	0.076	2.091	0.813-5.374	0.126
Other	1.986	0.410-9.619	0.394	6.073	1.125-32.772	0.036
Combination of CT or AAD						
No	1			1		
Yes	0.632	0.379-1.055	0.079	0.557	0.326-0.950	0.032

Figure S1. Key subgroups analysis of PFS (A) and OS (B).




Figure S1 A




Figure S1 B